Atrial Fibrillation Clinical Trial
— SAFE-VEINOfficial title:
Suture Closure AFtEr VEIN Access for Cardiac Procedures (SAFE-VEIN) Trial: A Randomized, Prospective Study of the Safety and Efficacy of Venous Closure Device Compared to Conventional Closure Strategies in Post Venous Access Procedures
NCT number | NCT04632641 |
Other study ID # | 20-235 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 23, 2021 |
Est. completion date | December 31, 2023 |
Verified date | April 2024 |
Source | Aurora Health Care |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Primary objective: To compare the safety and efficacy of closure strategies post venous access procedures. Hypothesis: We anticipate that the use of a venous closure device will decrease the time to hemostasis (TTH), time to ambulation (TTA) and time to discharge (TTD) compared to conventional methods of closure following venous access procedure.
Status | Completed |
Enrollment | 107 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria: Large-bore (>13F) Venous Access Procedures Inclusion Criteria: All patients 18 years and older who are undergoing any of the following: WATCHMAN® device placement, atrial fibrillation ablation using cryoballoon or laser balloon, leadless pacemaker, Pulmonary embolism thrombectomy (Inari FlowTriever system), MitraClip transcatheter mitral valve repair at Aurora St. Luke's Medical Center from date of IRB (Institutional Review Board) approval through December 2022. All arterial line access should be radial. Exclusion criteria: Large-bore (>13F) Venous Access Procedures Exclusion Criteria: - Patients in whom introducer sheaths >25F were used in the vein during the catheterization procedure. - Patients with small femoral arteries or veins (< 5 mm in diameter). - Patients with access sites in vascular grafts. - Patients with intra-procedural bleeding around access site. Patients who cannot receive radial arterial line access. - Patients who have complications during the procedure not related to the Perclose ProGlide SMC closure device - The physician determines that they must use an alternate method as the primary venous closure method other than that which the patient was randomized to - Active systemic or cutaneous infection, or inflammation in vicinity of the groin - Pre-existing immunodeficiency disorder or chronic use of high dose systemic steroids - Known history of bleeding diathesis, coagulopathy, hypercoagulability or platelet count < 100,000 cells/mm3 - Severe co-existing morbidities with life expectancy less than 12 months - Femoral arteriotomy or femoral venotomy in < 10 days, or with any known vascular complications or residual hematoma, or with use of an intravascular closure device w/in previous 30 days - Planned femoral venous or arterial access within next 30 days - Unable to routinely walk at least 20 ft. without assistance - LMWH (low molecular weight heparin) within 8 hours before or after procedure - Pregnant and/or lactating women - Extreme morbid obesity (BMI > 40 kg/m2) or underweight (BMI < 20 kg/m2) |
Country | Name | City | State |
---|---|---|---|
United States | Aurora St. Luke's Medical Center | Milwaukee | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
Aurora Health Care |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to Achieve Hemostasis | The elapsed time between "device" removal and first observed and confirmed venous hemostasis | Day 1 | |
Primary | Time to Ambulate | The elapsed time between removal of the final Perclose ProGlide SMC device (treatment arm) or removal of the final sheath (control arm), and the ability of subjects to stand and ambulate 20 feet without evidence of venous re-bleeding from the femoral access sites. | Day 1 | |
Secondary | Time to Discharge (TTD)/Length of Stay (LOS) | The elapsed time between removal of the final sheath, and the ability of subjects to be discharged. Total length of hospital stay. | up to 5 days post procedure | |
Secondary | Post Procedure Major Bleeding | Bleeding associated with =2 g/dl drop in hemoglobin level requiring transfusion, bleeding that occurs at a critical site, or bleeding contributing to death. | up to 30 days post procedure | |
Secondary | Minor Bleeding | Any bleeding that does not meet the criteria for major bleeding | up to 30 days post procedure | |
Secondary | Access Site Complications | Access site hematoma, vascular thrombosis, vascular dissection, pseudoaneurysm, or AV (arteriovenous) fistula | up to 30 days post procedure | |
Secondary | Mortality | Mortality due to vascular complications | up to 30 days post procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |